Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.


Autoria(s): Meijer S.L.; Dols A.; Hu H.M.; Chu Y.; Romero P.; Urba W.J.; Fox B.A.
Data(s)

2004

Resumo

Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62LLow) or high levels of CD62L (CD62LHigh). Effector T cells generated from CD62LLow cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion. Interestingly, effector T cells generated from CD62LLow or CD62LHigh TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62LLow T cells the type 1 cytokine profile appeared determined prior to culture. Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy.

Identificador

http://serval.unil.ch/?id=serval:BIB_3771552B28C2

isbn:0008-8749

pmid:15135291

doi:10.1016/j.cellimm.2004.01.006

isiid:000221528600002

Idioma(s)

en

Fonte

Cellular Immunology, vol. 227, no. 2, pp. 93-102

Palavras-Chave #Cancer Vaccines/immunology; Carcinoma, Renal Cell/immunology; Carcinoma, Renal Cell/therapy; Humans; Immunotherapy, Adoptive; Interferon-gamma/biosynthesis; Interleukin-5/biosynthesis; Kidney Neoplasms/immunology; Kidney Neoplasms/therapy; L-Selectin/analysis; Lymph Nodes/immunology; Melanoma/immunology; Melanoma/therapy; T-Lymphocytes/immunology
Tipo

info:eu-repo/semantics/article

article